Results 41 to 50 of about 1,466,034 (291)

Physical activity, exercise and cardiac troponins: Clinical implications.

Progress in cardiovascular diseases, 2019
Cardiac troponins constitute essential components of the cardiac contractile apparatus and are released into the bloodstream following cardiomyocyte injury.
K. Aakre, T. Omland
semanticscholar   +1 more source

Influence of case definition on incidence and outcome of acute coronary syndromes [PDF]

, 2016
© 2016, BMJ Publishing Group. All rights reserved. Objective: Acute coronary syndromes (ACS) are common, but their incidence and outcome might depend greatly on how data are collected.
Alamgir, Farqad, Atkin, Paul, Clark, Andrew L, Cleland, John G F, Goode, Kevin, Hoye, Angela, Kilpatrick, Eric, Panahi, Hossein, Rigby, Alan, Sherwi, Nasser, Thackray, Simon, Torabi, Azam   +11 more
core   +2 more sources

Monitoring of biomarkers in heart failure. [PDF]

, 2019
The role of biomarkers is increasingly recognized in heart failure (HF) management, for diagnosis, prognostication, and screening of high-risk patients.
Agewall, Agewall, Agewall, Agostoni, Andrew J S Coats, Ather, Bayes-Genis, Bhambhani, Binas, Broch, Demissei, Felker, Giuseppe M C Rosano, Graham, Greene, Hallén, Harjola, Hoedemaker, Ilaria Spoletini, Januzzi, Januzzi, Ky, McCarthy, Michele Senni, Mueller, Nadar, O'Meara, Pareek, Paul, Peacock, Perk, Ponikowski, Rastogi, Salmonson, Sarhene, Sato, Schneider, Shah, Squire, Stenemo, Tamargo, Troughton, Welsh, Xue   +43 more
core   +1 more source

Kinetics of 2 different high-sensitive troponins during targeted temperature management in out-of-hospital cardiac arrest patients with acute myocardial infarction: a post hoc sub-study of a randomised clinical trial

BMC Cardiovascular Disorders, 2022
Introduction Short term hypothermia has been suggested to have cardio protective properties in acute myocardial infarction (AMI) by reducing infarct size as assessed by troponins. There are limited data on the kinetics of these biomarkers in comatose out-
Alf Inge Larsen, Anders Morten Grejs, Simon Tilma Vistisen, Kristian Strand, Øyvind Skadberg, Anni Nørgaard Jeppesen, Christophe H. V. Duez, Hans Kirkegaard, Eldar Søreide   +8 more
doaj   +1 more source

Do we need another heart failure biomarker. focus on soluble suppression of tumorigenicity 2 (sST2) [PDF]

, 2016
If sST2 indeed turns into the HbA1c of heart failure, its value should increase exponentially in our management of patients with heart failure. Serial sST2 levels should allow us to titrate therapy and monitor the clinical state of the patient.
DI SOMMA, Salvatore, Maisel, Alan S
core   +1 more source

Serum Biomarkers for the Detection of Cardiac Toxicity after Chemotherapy and Radiation Therapy in Breast Cancer Patients

Frontiers in Oncology, 2014
Multi-modality cancer treatments that include chemotherapy, radiation therapy, and targeted agents are highly effective therapies. Their use, especially in combination, is limited by the risk of significant cardiac toxicity.
Sibo eTian, Kim M Hirshfield, Salma K Jabbour, Deborah eToppmeyer, Bruce George Haffty, Atif J Khan, Sharad eGoyal   +6 more
doaj   +1 more source

Direct Comparison of Cardiac Myosin-Binding Protein C With Cardiac Troponins for the Early Diagnosis of Acute Myocardial Infarction

Circulation, 2017
Background: Cardiac myosin-binding protein C (cMyC) is a cardiac-restricted protein that is more abundant than cardiac troponins (cTn) and is released more rapidly after acute myocardial infarction (AMI). We evaluated cMyC as an adjunct or alternative to
T. Kaier, R. Twerenbold, C. Puelacher, J. Marjot, Nazia Imambaccus, J. Boeddinghaus, T. Nestelberger, P. Badertscher, Z. Sabti, M. Gimenez, K. Wildi, P. Hillinger, Karin Grimm, Sarah Loeffel, S. Shrestha, D. Widmer, Janosch Cupa, N. Kozhuharov, Ò. Miró, F. Martín-Sánchez, B. Morawiec, K. Rentsch, J. Lohrmann, Wanda Kloos, S. Osswald, T. Reichlin, E. Weber, M. Marber, C. Mueller   +28 more
semanticscholar   +1 more source

Type 2 myocardial infarction: the chimaera of cardiology? [PDF]

, 2015
The term type 2 myocardial infarction first appeared as part of the universal definition of myocardial infarction. It was introduced to cover a group of patients who had elevation of cardiac troponin but did not meet the traditional criteria for acute ...
[No authors listed], [No authors listed], Ammann, Apple, Assomull, Babuin, Bakshi, Baron, Bonaca, Botto, Collinson, Collinson, Collinson, Collinson, Cummins, Cummins, Davies, Davies, Falk, Gerhardt, Guest, Hamm, Javed, Jesse, Katus, Keller, Kollef, Latini, Lindahl, Melanson, Melberg, Morrow, Ohman, Ostermann, Ravkilde, Reichlin, Saaby, Saaby, Sandoval, Smith, Stein, Stubbs, Szymanski, Thygesen, Thygesen, Thygesen, Wu   +46 more
core   +1 more source

CHEMOTHERAPY CARDIOTOXICITY SCREENING WITH CARDIAC TROPONINS

Российский кардиологический журнал, 2015
Recently, chemotherapy is one of the most trustworthy methods for treatment of malignant tumors and blood pathology. However clinical effect of the drugs not always matches with safety.
O. V. Krikunova, Yu. A. Vasyuk, R. V. Viskov, P. V. Krikunov, S. V. Ivanova, V. A. Konik   +5 more
doaj   +1 more source

One-year in vitro stability of cardiac troponins and galectin-3 in different sample types.

Clinica chimica acta; international journal of clinical chemistry, 2018
BACKGROUND We assessed the long-term in vitro stability of cardiac troponins and galectin-3 under different storage conditions. METHODS We used high-sensitivity cardiac troponin I (hs-cTnI) and galectin-3 assays from Abbott and a high-sensitivity ...
M. Egger, B. Dieplinger, T. Mueller
semanticscholar   +1 more source